Document Detail

Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine.
MedLine Citation:
PMID:  17696566     Owner:  NLM     Status:  MEDLINE    
Direct thrombin inhibitors have several potential advantages over indirect thrombin inhibitors such as heparin. Bivalirudin, a bivalent direct thrombin inhibitor, is most commonly used in clinical practice and has a proven role in contemporary interventional medicine with elective percutaneous coronary intervention (PCI) as well as in patients with non-ST-elevation acute coronary syndrome (NSTEACS). Results from well-controlled clinical trials have shown that bivalirudin is associated with an approximate 50% reduction in major bleeding while having similar effects on incidence of death and myocardial infarction (MI) compared with herapin or enoxaparin and glycoprotein IIb/IIIa inhibitors. Bivalirudin has been successfully used in off- and on-pump cardiac surgery. Argatroban is the most evaluated among the univalent direct thrombin inhibitors inhibiting only the catalytic site of thrombin. It has been associated with similar rates of major bleeding compared with heparin in patients with acute MI receiving either streptokinase or alteplase with no effects on clinical endpoints. In a meta-analysis of 11 randomised trials where direct thrombin inhibitors (hirudin, bivalirudin, argatroban, efegatan or inogatran) were compared with unfractionated heparin in >35,000 patients with ST-elevation MI (STEMI) or NSTEACS there was no mortality difference between treatment groups but the incidence of MI at 30 days was significantly reduced in patients treated with direct thrombin inhibitors compared with heparin (4.7% vs 5.3%; p < 0.004). The role of direct thrombin inhibitors in both primary angioplasty for STEMI and angioplasty after fibrinolytic therapy needs to be established. Overall, the efficacy and improved safety profile make bivalirudin an attractive first-line anticoagulant for elective PCI and in patients with NSTEACS undergoing an invasive strategy.
Cheuk-Kit Wong; Harvey D White
Related Documents :
2189186 - An evaluation of central laboratories in three va cooperative studies.
14574076 - Clinician update: direct thrombin inhibitors in acute coronary syndromes.
1576116 - Persistent generation of thrombin after acute myocardial infarction.
17313616 - Clinical use of clopidogrel in acute coronary syndrome.
19346846 - Quantitative evaluation of regional left ventricular function by multidetector computed...
6705156 - Myocardial injury and induction of arrhythmia by direct current shock delivered via end...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of cardiovascular drugs : drugs, devices, and other interventions     Volume:  7     ISSN:  1175-3277     ISO Abbreviation:  Am J Cardiovasc Drugs     Publication Date:  2007  
Date Detail:
Created Date:  2007-08-16     Completed Date:  2007-11-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100967755     Medline TA:  Am J Cardiovasc Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  249-57     Citation Subset:  IM    
Dunedin School of Medicine, Cardiology, Otago University, Otago, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary
Anticoagulants* / adverse effects,  pharmacology,  therapeutic use
Heparin / adverse effects
Hirudins* / adverse effects,  pharmacology
Myocardial Infarction / drug therapy,  therapy
Peptide Fragments* / adverse effects,  pharmacology,  therapeutic use
Recombinant Proteins / adverse effects,  pharmacology,  therapeutic use
Renal Insufficiency
Thrombin / antagonists & inhibitors*
Thrombocytopenia / chemically induced,  drug therapy
Reg. No./Substance:
0/Anticoagulants; 0/Hirudins; 0/Peptide Fragments; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 9005-49-6/Heparin; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacologic therapy of chronic heart failure.
Next Document:  Metabolic syndrome: cardiovascular risk assessment and management.